NCT00611572已完成1 期
Contribution of Gabaergic and Glutamatergic Mechanisms to Cognitive Dysfunction
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- P300 as an ERP measure
研究概览
简要总结
This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Active Comparator
Active iomazenil and ketamine
干预措施: iomazenil (Drug)
2
Placebo Comparator
placebo iomazenil and ketamine
干预措施: iomazenil (Drug)
结局指标
主要结局
P300 as an ERP measure
时间窗: prospective
次要结局
- MMN (Mismatch Negativity)(prospective)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Biomarkers in SchizophreniaSchizophreniaSchizoaffective DisorderNCT00817336Nathan Kline Institute for Psychiatric Research16
已完成
不适用
Cortical GABA Concentrations in InsomniaMajor DepressionInsomniaNCT00765752Yale University23
进行中（未招募）
1 期
Pharmacogenetics of GABAergic mechanisms of benefit and harm in epilepsy: : A prospective cohort study to determine the enviromental and genetic factors associated with response to clobazam. - Pharmacogenetics:clobazamEpilepsyEUCTR2004-003945-41-GBliverpool university400
进行中（未招募）
1 期
Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndrome22q11.2 deletion syndromeEUCTR2021-002011-61-NLAcademisch ziekenhuis Maastricht45
招募中
4 期
The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndromeNL-OMON52172Medisch Universitair Ziekenhuis Maastricht46